A FTSE 100 super growth stock I’d spend £2,000 on today

This FTSE 100 (INDEXFTSE: UKX) stock is in great shape to keep doling out delicious earnings growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors sifting the FTSE 100 for super growth stocks can do a lot worse than to tap into NMC Health (LSE: NMC), in my opinion.

The company is a major provider of private healthcare in the United Arab Emirates, and has already seen earnings swell at a compound annual growth rate of 23% over the past half a decade. And City analysts are predicting that profits are about to pick up speed in 2018, a 45% advance currently being anticipated. An extra 23% advance is forecast for 2019.

Yet despite its proven growth credentials NMC Health can still be picked up for next to nothing. Look past a forward P/E ratio of 33.5 times and this becomes apparent, its corresponding PEG reading standing at a sub-1 reading of 0.7.

M&A mammoth

What’s more, NMC Health carries a bonus in that dividends are expected to keep growing at a stratospheric rate just like earnings. In 2018 the shareholder reward is expected to fly to 19p per share from 13p last year, and again to 24 cents in 2019. These projections yield 0.5% and 0.7% respectively.

It’s not difficult to see why the Square Mile is so bullish on the healthcare star’s profits outlook. A combination of rising population levels and personal incomes in its developing regions should lay the path for strong and sustained profits advances long into the future.

And NMC Health is investing heavily in its operations to capitalise on these fertile conditions. Thanks to a string of asset acquisitions in recent times, the number of hospital beds on its books doubled in 2017 to 1,365 from 679 a year earlier.

The acquisition hunt shows little sign of slowing. In February the Footsie firm boosted its footprint in Saudi Arabia by securing an 80% holding in the Al Salam Medical Group for an initial $37m, a deal that includes a 100-bed hospital as well as two medical centres. It also secured a 70% stake in cosmetics surgery specialist CosmeSurge for $170m.

Just RELX

Another FTSE 100 super growth stock worthy of your attention today is RELX (LSE: RELX).

Recent annual growth may not be as impressive as that of NMC Health, but the bottom line has still swelled by double-digit percentages over the past couple of years. And like the hospital provider, thanks to its decent revenues prospects on foreign shores, the Square Mile’s army of brokers is expecting earnings to continue stomping higher.

Rises of 4% and 5% are forecast for 2018 and 2019 respectively and this leads to predictions of meaty dividend growth as well — last year’s payment of 39.4p per share is expected to stride to 42.2p in the current period and to 44.8p in 2019. Yields stand at a meaty 2.8% for this year and 2.9% for next year as a consequence.

And solid market commentary released this week convince me that RELX should make good on these estimates. The information and analytics provider advised that it is confident it should “deliver another year of underlying growth in revenue and in adjusted operating profit.”

With the business also busy on the M&A front — it has made four acquisitions since the turn of 2018 for an aggregated £668m — the outlook is also bright here. I believe solid market conditions and exciting portfolio reshaping makes RELX worthy of a slightly-toppy forward P/E multiple of 18.1 times.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended RELX. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »